Rising Growth of Pharmaceutical Companies in Terms of Research and Production Medications Is Driving the Immunotoxins Market

Rising Incidences of Cancer is Anticipated to Drive the Immunotoxin Market during the forecast period 2021-2026. Immunotoxin Market Size Was Valued at $46.8 Million in 2020, Growing at a CAGR of 7.8% During the Forecast Period 2021-2026.

The Immunotoxin Market is growing at a significant rate owing to the increase in cancer incidence. According to World Health Organization, cancer is the second leading cause of death and about 15 million people are suffering from cancer in 2020 which increases the demand of immunotoxins and is driving the growth of this market. Immunotoxins are new tools that are very useful in the treatment of circulating tumor cells expressing a high number of target proteins and helps to kill the cancer cells which increases the demand of immunotoxins. According to National Cancer Institute, in 2019 approximately 39.5% of men and women are diagnosed with cancer and the incidence rate of cancer is higher among men than women which thereby increasing the product demand. In 2019, about 16.9 million cases are suffering from cancer in the U.S. and according to National Cancer Institute, the number of cancer cases are estimated to increase to 22.2 million by 2030 that are increasing the demand of immunotoxin and are driving the growth of this market.

Immunotoxins are proteins that consist of monoclonal antibody which are linked to a toxic molecule. This toxic molecule is derived from plant origin that helps to kill cancer cells. Bacterial toxins are most commonly used in immunotoxins which include Diphtheria toxin (DT) and the toxin from Pseudomonas exotoxin (PE). Increasing development of advance and efficient technology is projected to significantly boost the growth of Immunotoxin market in the forecast period 2021-2026. In 2019, According to National Cancer Institute, various immunotherapy drugs has been approved to treat many types of cancer in different forms such as intravenous, oral and others that helps to treat cancer to various cancer patients are driving the growth of this market. Diphtheria toxin (DT) is an extracellular protein of Corynebacterium diphtheriae that inhibits protein synthesis and kills susceptible cells which is set to increase the demand of this segment. Diphtheria toxin used as a toxin element in the construction of immunotoxin for cell specific cytotoxicity are increasing demand for Immunotoxins Market. The gene for Diphtheria Toxin (DT) comes from a lysogenic prophage that integrates its genome with C. Diphtheriae plasmids. The gene is translated and secreted as a single, 535-residue polypeptide chain and consists of two major subunits, known as A and B. 

North America holds a major share of Immunotoxin market owing to increasing usage of immunotoxins to treat patients with refractory hairy cell leukemia which is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes is increasing the growth of the Immunotoxins Market. The Public Health Agency of Canada, in collaboration with other governmental and non-governmental organizations, conducts national surveillance of cancer to support the planning and evaluation of cancer-related policies, programs, and services is set to drive the growth in this region. Advantages of immunotoxins are minimum toxicity in normal tissues, discerning cytotoxicity towards tumor cells along with the increasing development in the treatment of solid tumors has been impeded in part, by the initiation of an immune response directly. Changes in health care policies in Mexico have incorporated programmers for access to early diagnosis and treatment of this disease through immunotoxins. Immunotoxins demand is increasing in Mexico owing to the low mammography coverage, poor quality control, limited access to diagnosis and treatment, and insufficient physical and human resources for clinical care, further aids to the growth of the market in this region. The unique mechanism of action for inhibiting protein synthesis in cancer cells makes immunotoxins a viable class of antibody drugs that are distinct from others, including bispecific antibodies and antibody–drug conjugate, stimulating the growth of the Immunotoxins market during the forecast period 2021-2026. Rising government initiatives for the development of immunotoxin such as FDA approval that helps to treat cancer patients in this region is further bolstering the growth of Immunotoxin systems market in U.S., Canada and Mexico is set to avail new growth opportunity to Immunotoxin market during 2021-2026.

 

Increasing research of immunotoxins in bone marrow transplantation and rising new developments in monoclonal antibody technology as well as in the molecular design of toxins are created new clinical application in organ transplantation and bone marrow transplantation which increases opportunities for the market growth. The system to remove the bone marrow of myeloma cells has been developed in laboratories with the aim of treating with myeloablative radiochemotherapy patients suffering from advanced multiple myeloma. This system is based on the ex vivo incubation of the marrow with an immunotoxin composed of the 8A monoclonal antibody that recognizes plasma cells and B‐cell precursors that are increasing opportunities for the growth of Immunotoxins Market. Moreover, treatment of donor bone marrow with FabT101 Ricin A-Chain Immunotoxin for the Prevention of Graft-versus-Host Disease also increases the demand of immunotoxin. 

Initiatives taken by the government across the globe for the development of immunotoxin such as FDA approval help in the treatment of cancer patients thereby, increasing the demand of the market. According to National Cancer Institute, about 606 million people are died owing to cancer in 2020. So, the increasing cancer cases increases the initiatives among the government to reduce death cases that are driving the growth of this market.

 

Thermo Fisher Scientific has signed agreement with Terasaki Innovation Center (TIC) to facilitate discovery and development of new pathways and tools to diagnose patients.

The major companies in the Immunotoxin market include Thermo Fisher Scientific, Merck KGaA, Creative Biolabs, The Native Antigen Company, List Biological Laboratories Inc. and others. In April 2019, Meridian Bioscience, Inc. acquired the business of GenePOC Inc., a Quebec City, Quebec, Canada based provider of molecular diagnostic instruments and assays. This acquisition helped meridian’s portfolio of molecular diagnostics portfolio.

Over the years, companies have mainly focused on offering a wide range of products for Immunotoxin and have vast geographical presence globally, thereby augmenting their respective positions in the market. Manufacturers in this market are involved into the production of more Immunotoxin products which are preferred by healthcare officials. Rising number new manufacturers producing Immunotoxin products are set to increase in the degree of competition and are the major factors set to buoy the Immunotoxin market during 2021-2026.